Advanced degree in health research (e.g., pharmacoeconomics) and/or comparable training as well as work experience applicable to the collection, analysis, and reporting of real-world data; Minimum 5 years of relevant work experience; Strong experience in SAS, Stata, or R programming, as well as analytic and statistical methods; Knowledge of comparative effectiveness research, observational studies, medication adherence, economic evaluation, pharmacoeconomic modeling, and risk benefit methods; Experience with the application of outcomes research in health care decisions; Experience in providing HEOR input into study protocol design, writing analysis plans, and external reporting of health services research; Knowledge of, and experience with medical terminology, medical coding, and gastrointestinal diseases (or multiple therapeutic experience); Good organizational and problem-solving skills; Detail-oriented with strong quantitative, written, and communication skills; A person who can understand and clearly communicate complex information; Excels in a collaborative team-oriented environment; Must be able to manage multiple initiatives and shifting priorities within a small company environment; Occasional travel. Ironwood is also advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure, as well as several earlier stage assets.